Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Okta, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Okta, Inc. trades at $204.25 (market cap $37.05B). The key difference: Okta, Inc. is far larger — about 37.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Okta, Inc. for 44 Days on average.
| MRVI | OKTA | |
|---|---|---|
Market Cap | $977.37M | $37.05B |
Volume | 2,742,564 | 4,638,855 |
Sector | Health | Technology |
52-Week High | $9.00 | $232.13 |
52-Week Low | $2.83 | $62.93 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $1.08B | $34.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
OKTA trades at $226.53, showing modest daily weakness with a 0.24% decline. The stock maintains strong bullish technical momentum with consistent earnings beats and positive analyst sentiment. Recent developments include the company's AI Agent Security Blueprint Alliance announcement at Oktane 2026, positioning Okta for growth in the emerging AI security market. Fundamental improvements show revenue growth from $2.3B in 2024 to $2.6B in 2025, with the company achieving profitability after several years of losses.
Outlook remains positive with 74% analyst buy ratings and a $245 high price target, though valuation multiples appear stretched with P/E of 136. Key risks include competitive pressures in cybersecurity and the stock's premium valuation. The transition to profitability and AI security positioning provide catalysts, but investors should monitor execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
